Androgen receptor splice variant 7 detected by immunohistochemical is an independent poor prognostic marker in men receiving adjuvant androgen-deprivation therapy after radical prostatectomy

Wei Ouyang,Man Liu,Chunguang Yang,Shaogang Wang,Hua Xu,Wei Guan,Zhihua Wang,Yucong Zhang,Gongwei Long,Heng Li,Xing Zeng,Xiaming Liu,Fan Li,Zhiquan Hu,Jun Yang,Zheng Liu,Guoliang Sun,Zhangqun Ye,Xiao Yu

doi:10.1186/s40364-021-00276-x

Wei Ouyang, Man Liu + Show 17 more

Open Access

https://doi.org/10.1186/s40364-021-00276-x

Copy DOI

Abstract

BackgroundTo evaluate the predictive value of AR-V7 expression detected by immunohistochemical (IHC) in the prognosis of prostate cancer patients receiving adjuvant hormonal therapy (AHT) following radical prostatectomy (RP).MethodsWe retrospectively collected data of 110 patients with prostate cancer receiving RP, followed by AHT, from Tongji hospital. IHC analysis of AR-V7 expression was performed in a retrospective cohort.ResultsIn total, 110 patients were enrolled, of whom 21 patients (19.1%) were AR-V7-positive and 89 patients (80.9%) were AR-V7-negative. No significant differences in baseline characteristics were found between the two groups. AR-V7-positive patients had shorter progression-free survival (PFS) (HR: 4.26; 95% CI, 1.55 to 11.68; P = 0.003), shorter cancer-special survival (CSS) (HR: 22.47; 95% CI, 2.912 to 173.4; P = 0.003) and shorter overall survival (OS) (HR: 6.61; 95% CI, 1.40 to 31.20; P = 0.017) compared to AR-V7-negative patients. In multivariate analysis, AR-V7 is an independent risk factor for shorter PFS (HR, 3.76; 95% CI, 1.63 to 8.70; P = 0.002), shorter CSS (HR: 9.17; 95% CI, 1.48 to 55.56; P = 0.017) and shorter OS (HR: 4.81; 95% CI, 1.28 to 17.86; P = 0.020).ConclusionThe presence of AR-V7 in prostate cancer tissue is independently associated with an unfavorable prognosis for PFS, OS and CSS in patients who received AHT.

Highlights

It was estimated that there were almost 1.3 million new cases of prostate cancer and 359,000 associated deaths worldwide in 2018, ranking as the second most frequent cancer and the fifth leading cause of cancer death in men [1]
androgen receptor (AR)-V7positive patients had shorter progression-free survival (PFS) (HR: 4.26; 95% CI, 1.55 to 11.68; P = 0.003), shorter cancerspecial survival (CSS) (HR: 22.47; 95% CI, 2.912 to 173.4; P = 0.003) and shorter overall survival (OS) (HR: 6.61; 95% CI, 1.40 to 31.20; P = 0.017) compared to Androgen Receptor Splice Variant 7 (AR-V7)-negative patients
AR-V7 is an independent risk factor for shorter PFS (HR, 3.76; 95% CI, 1.63 to 8.70; P = 0.002), shorter CSS (HR: 9.17; 95% CI, 1.48 to 55.56; P = 0.017) and shorter OS (HR: 4.81; 95% CI, 1.28 to 17.86; P = 0.020)

Summary

Introduction

It was estimated that there were almost 1.3 million new cases of prostate cancer and 359,000 associated deaths worldwide in 2018, ranking as the second most frequent cancer and the fifth leading cause of cancer death in men [1] It is the most frequently diagnosed cancer among men in over one-half (105 of 185) of the countries around the world. The difference between the two groups was insignificant for overall survival (OS) Another clinical analysis showed the efficacy of bicalutamide as an adjuvant treatment after RP for locally advanced, nonmetastatic prostate cancer, and concluded that bicalutamide could prolong the PFS versus standard care alone, but not OS [12]. To evaluate the predictive value of AR-V7 expression detected by immunohistochemical (IHC) in the prognosis of prostate cancer patients receiving adjuvant hormonal therapy (AHT) following radical prostatectomy (RP)

Objectives

Methods

Results

Discussion

Conclusion